Business Context and Reporting Period
This Form 8-K was filed by Capricor Therapeutics, Inc. on February 27, 2015, reporting a material definitive agreement entered into on that date. The company, a Delaware corporation, operates in the biotechnology sector with principal executive offices in Beverly Hills, California.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial figures disclosed relate to the terms of a new license amendment:
- Upfront Fee: $20,000 payable to Cedars-Sinai Medical Center (CSMC).
- Reimbursement: Approximately $34,000 for attorneys' and filing fees.
- Milestone Payments: Range from $15,000 (Phase I dosing) to $75,000 (FDA approval).
- Maximum Aggregate Milestones: $190,000.
Material Changes
The primary material change is the execution of the First Amendment to the Exclusive License Agreement with CSMC. Key modifications include:
- Expansion of patent rights via a Revised Schedule A, adding four new patent applications.
- Establishment of new payment obligations including the upfront fee, fee reimbursement, and defined product development milestones.
Outlook, Risks, and Related Parties
Related Party Transactions: The agreement involves CSMC, which holds more than 10% of Capricor Therapeutics' outstanding capital stock. Additionally, Dr. Eduardo Marbán, a significant shareholder (holding >10%), serves as the Director of the Cedars-Sinai Heart Institute and Co-founder/Scientific Advisory Board Chairman of Capricor.
Confidentiality: The company intends to seek confidential treatment for certain terms of the amendment and expects to file the full text as an exhibit to a future required filing.
Risks: Future cash outflows are contingent upon reaching specific clinical study phases and obtaining FDA approval.
Investor Verification Checklist
- Verify the full text of the Exosomes License Amendment when filed to review confidential terms.
- Confirm the status of the four additional patent applications added to Schedule A.
- Monitor the company's cash position relative to the immediate $54,000 cash outflow ($20,000 fee + $34,000 reimbursement).
- Review the related party disclosures regarding CSMC and Dr. Marbán for potential conflicts of interest.